Comparison of estrogen receptor-α, progesterone receptor and calponin expression in gonadotrophinreleasing hormone agonist-sensitive and -resistant uterine fibroids = Comparison of estrogen receptor-α, progesterone receptor and calponin expression in gonadotrophinreleasing hormone agonist-sensitive and -resistant uterine fibroids

다국어 초록 (Multilingual Abstract)

Objective This study was aimed to compare immunohistochemical expression of estrogen receptor (ER)-α, progesterone receptor (PR), and calponin in gonadotrophin-releasing hormone agonist (GnRH-a)-sensitive and -resistant uterine fibroids. Methods We collected data retrospectively. The sensitive group consisted of women who had reduction in uterine volume greater than 40% following GnRH-a treatment. Uterine volume was either reduced by less than 10%, or was increased in the resistant group. A tissue microarray was constructed using formalin-fixed, paraffin-embedded tissues, 31 and 26 patients for the sensitive and resistant groups, respectively. Tissue sections were immunostained with antibodies against ER-α, PR, and calponin. The intensity and area of the immunohistochemical reactions were evaluated using a semi-quantitative scoring system. The Mann-Whitney U-test, Fisher`s exact test, and Spearman`s rank correlation test were used for analysis of data. Results PR ( P = 0.04) and calponin ( P = 0.03) showed a significantly higher staining intensity in the resistant group than in the sensitive group. Both groups showed comparable expression of ER-α ( P = 0.23). In correlation analysis between changes in uterine volume after GnRH-a therapy and clinicopathological factors, the immunohistochemical intensity of PR ( P = 0.04) and calponin ( P = 0.03) was significantly correlated with changes in uterine volume. Conclusion This study shows that GnRH-a resistance of uterine fibroids is not related to ER-α content, but the expression of PR and calponin is related with GnRH-a resistance.

참고문헌 (Reference)

1 Adamson GD, "Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists" Am J Obstet Gynecol 166 : 746 ~ 751, 1992

2 Reinsch RC, "The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study" Am J Obstet Gynecol 170 : 1623 ~ 1627, 1994

3 Millan Y, "Steroid receptors in canine and human female genital tract tumours with smooth muscle differentiation" J Comp Pathol 136 : 197 ~ 201, 2007

4 Vollenhoven BJ, "Steroid receptor binding and messenger RNA expression in fibroids from untreated and gonadotrophin-releasing hormone agonist pretreated women" Clin Endocrinol (Oxf) 40 : 537 ~ 544, 1994

5 Thor AD, "Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism" J Natl Cancer Inst 85 : 176 ~ 177, 1993

6 Nakayama M, "Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas" Pathol Int 58 : 268 ~ 274, 2008

7 Maheux R, "Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study" Am J Obstet Gynecol 152 : 1034 ~ 1038, 1985

8 Zhu XQ, "Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma" Gynecol Oncol 92 : 71 ~ 79, 2004

9 Horiuchi A, "Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alphasmooth muscle actin, calponin h1 and p27" Mol Hum Reprod 5 : 139 ~ 145, 1999

10 Harrison-Woolrych M, "Fibroid growth in response to high-dose progestogen" Fertil Steril 64 : 191 ~ 192, 1995

11 Cirkel U, "Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone. Analogue depot therapy" Acta Obstet Gynecol Scand 73 : 328 ~ 332, 1994

12 Wilson EA, "Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissues" Obstet Gynecol 55 : 20 ~ 24, 1980

13 Lethaby A, "Efficacy of preoperative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review" BJOG 109 : 1097 ~ 1108, 2002

14 Watanabe Y, "Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women" Fertil Steril 58 : 66 ~ 71, 1992

15 Tamaya T, "Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium" Acta Obstet Gynecol Scand 64 : 307 ~ 309, 1985

16 Hong DG, "Analysis of factors affecting vaginal hysterectomy" Minim Invasive Ther Allied Technol 18 : 317 ~ 321, 2009

17 Filicori M, "A conservative approach to the management of uterine leiomyoma: pituitary desensitization by a luteinizing hormone-releasing hormone analogue" Am J Obstet Gynecol 147 : 726 ~ 727, 1983